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Current iron chelation therapy consists primarily of DFO (desfer-
rioxamine), which has to be administered via intravenous infusion,
together with deferiprone and deferasirox, which are orally-active
chelators. These chelators, although effective at decreasing the
iron load, are associated with a number of side effects. Grady
suggested that the combined administration of a smaller bidentate
chelator and a larger hexadentate chelator, such as DFO, would
result in greater iron removal than either chelator alone [Grady,
Bardoukas and Giardina (1998) Blood 92, 16b]. This in turn
could lead to a decrease in the chelator dose required. To test
this hypothesis, the rate of iron transfer from a range of bidentate
HPO (hydroxypyridin-4-one) chelators to DFO was monitored.
Spectroscopic methods were utilized to monitor the decrease in
the concentration of the Fe–HPO complex. Having established
that the shuttling of iron from the bidentate chelator to DFO
does occur under clinically relevant concentrations of chelator,
studies were undertaken to evaluate whether this mechanism of
transfer would apply to iron removal from transferrin. Again, the
simultaneous presence of both a bidentate chelator and DFO was
found to enhance the rate of iron chelation from transferrin at
clinically relevant chelator levels. Deferiprone was found to be
particularly effective at ‘shuttling’ iron from transferrin to DFO,
probably as a result of its small size and relative low affinity for
iron compared with other analogous HPO chelators.
Key words: deferiprone; desferrioxamine (DFO); hydroxypyridin-
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INTRODUCTION
Although current chelation therapy is effective at improving
the life expectancy of individuals with transfusion-dependent
anaemias, its use causes numerous disadvantages. DFO (desfer-
rioxamine) is not orally active and must be administered by
subcutaneous infusion over 8 h periods up to five times per
week. This property decreases compliance with the drug. Two
orally active iron chelators have also been approved for clinical
use: deferasirox [1] and deferiprone (1,2-dimethyl-3-hydroxypy-
ridin-4-one) [2]. A comparative study of the safety and efficacy
of deferiprone and DFO in β-thalassaemia major patients
demonstrated that both chelators have a similar ability to remove
iron from the liver, but a greater increase in cardiac function was
observed with deferiprone treatment [3]. Interest in the application
of iron chelators in the treatment of non-iron overload diseases
has also increased over the last 5 years, with considerable effort
concentrated in two important fields, the treatment of cancer [4]
and the treatment of neurodegeneration [5,6].
It has been suggested previously that the combined adminis-
tration of a bidentate and a hexadentate chelator can lead to
enhanced scavenging of iron from certain iron-containing proteins
[7]. In principle, the smaller, kinetically labile bidentate chelator
can rapidly access intracellular iron pools. The scavenged iron
is subsequently transferred to the kinetically inert hexadentate
chelator, forming a more stable complex, which is excreted. In
this way, the bidentate chelator acts as a ‘shuttle’ molecule and
the hexadentate chelator as a ‘sink’. The concept of combined
chelation therapy has been utilized previously to remove excess
metals from the body in the cases of both plutonium and cad-
mium poisoning [8]. For instance, a combination of DTPA
(diethylenetriaminepentacetic acid) and salicylic acid was utilized
in the removal of plutonium. Combined administration of these
two chelators had a greater effect than either DTPA or salicylic
acid alone.
Enhanced scavenging, if it occurs, would be dependent on the
transfer of iron from the bidentate to the hexadentate chelator
(Scheme 1). Therefore it is of interest to investigate whether
appreciable rates of transfer can occur at clinically relevant
chelator concentrations.
It has been established previously that DFO cannot remove
iron from transferrin at physiological concentrations, probably as
a result of its relatively large size [9]. However, it is hypothesized
that in the presence of a smaller bidentate chelator, iron could be
transferred from transferrin to DFO. Experiments investigating
the possible synergistic effects of combined administration of
chelators in the removal of iron from transferrin have been
carried out previously [10,11]. However, these studies were
undertaken using high chelator concentrations. The observation
that deferiprone is able to chelate transferrin-bound iron [9]
indicates that it may also be able to access other iron pools that
are inaccessible to DFO. Thus the combination of deferiprone
with DFO may permit the chelation of iron, which would not
normally be removed by DFO therapy alone. As deferiprone has
been shown to be able to access and remove iron from cardiac
tissue [3], the combination of deferiprone and DFO, for instance,
might be expected to facilitate the removal of cardiac iron more
efficiently.
This paper investigates the transfer of iron from bidentate
chelators to DFO in an attempt to establish whether appreciable
Abbreviations used: DFO, desferrioxamine; DTPA, diethylenetriaminepentacetic acid; FO, ferrioxamine; HPO, hydroxypyridin-4-one; NTA, nitrilotriacetic
acid.
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Scheme 1 The proposed mechanism of iron transfer from Fe–HPO to DFO
The fully co-ordinated Fe(HPO)3 complex exists in equilibrium with the partially co-ordinated Fe(HPO)2 complex in solution. DFO is able to form a ternary complex with Fe(HPO)2 and subsequently
displace the remaining HPO molecules from iron.
Table 1 Structure of hydroxypyridin-4-ones
Position
Chelator R1 R2 R6 Reference
Deferiprone CH3 CH3 H [12]
CP40 CH2CH2OH CH3 H [12]
CP95 CH2CH2CH3 C2H5 H [12]
CP357 CH3 CH2NHCOCH2CH2NHCOCH3 CH3 [13]
CP358 CH3 CH2NHCOCH2CH2CONHC3H7 CH3 [13]
CP363 CH3 CH(CH3)OCH3 CH3 [14]
CP375 CH3 CH(C2H5)OCH3 CH3 [15]
CP502 CH3 CONHCH3 CH3 [12]
CP511 H CONHCH3 CH3 [16]
rates are achievable under clinical conditions, and whether this
phenomenon will lead to an increase in the rates of iron removal
from transferrin when compared with either chelator alone.
EXPERIMENTAL
Materials
Deferiprone was purchased from Sigma. Nine HPO (hydroxy-
pyridin-4-one) chelators were used in this study and each was
prepared as described previously [12–16]. These chelators fall
into three main categories: the low-affinity chelators (deferiprone,
CP95 and CP40: pFe3+ < 20), chelators with a large ring
substituent (CP357 and CP358) and the high-affinity chelators
(CP363, CP375, CP502 and CP511: pFe3+ > 20). The pFe3+ value
is defined as − log [Fe3+] with 1 µM total iron and 10 µM total
ligand at pH 7.4. The structures of these chelators are presented in
Table 1. All chemicals required for urea gel electrophoresis were
purchased from National Diagnostics (Atlanta, GA, U.S.A.). All
other chemicals were purchased from Sigma.
Purification of transferrin
Commercially available transferrin was not utilized for the iron
removal studies since these preparations are frequently con-
taminated with other proteins and low molecular-mass molecules,
which could interfere with the iron removal process. The presence
of such low molecular-mass contaminants, such as citrate,
could facilitate the transfer of iron from transferrin to DFO,
thereby resulting in artefacts. For these reasons, transferrin was
purified from human serum. Solid ammonium sulfate was added
to the serum sample (approx. 500 ml) to give a 45% (w/v)
saturated solution. The amount of ammonium sulfate required
was calculated as described previously [17]. The solution was
left stirring overnight at 4 ◦C and subsequently centrifuged at
8000 g for 30 min at 4 ◦C. Further ammonium sulfate was added
to the supernatant to increase the saturation to 70% (w/v), and
the solution was left to equilibrate by stirring for 3 h at 4 ◦C. The
solution was then centrifuged at 16000 g for 1 h at 4 ◦C, after
which the supernatant was discarded and the pellet was redis-
solved in 50 mM sodium bicarbonate solution. The sample
was then dialysed using 12 kDa molecular-mass cut-off tubing
(Medicell International, London, U.K.) overnight against de-
ionized water at 4 ◦C to remove the ammonium sulfate. Fe–NTA
(nitrilotriacetic acid) solution (0.1 M) was added to completely
saturate the transferrin present in the sample. The volume of
0.1M Fe–NTA required for saturation was calculated as stated
in the following equation:
Fe−NTA vol. = (2 × transferrin mol.) × transferrin vol.
Fe−NTA mol. (1)
where mol. is the molarity and vol. is the volume in µl. In all
cases, Fe–NTA was prepared by the addition of the free acid to
ferric chloride in a 1:1 ratio. This solution was freshly prepared
at the time of use. Sodium bicarbonate was then added to the
solution to a final concentration of 5 mM, together with Tris/HCl
(pH 8.0), which was added to a final concentration of 10 mM.
c© The Authors Journal compilation c© 2008 Biochemical Society
Iron removal from transferrin 441
The partially purified transferrin was applied to a DEAE–
Sepharose column (30 cm × 4 cm radius) equilibrated with
500 ml 20 mM Tris/HCl (pH 8.0). Both albumin and caerulo-
plasmin have a greater net negative charge than transferrin, and
therefore displace it from the DEAE–Sepharose column. As the
solution was passed through the column, albumin and caerulo-
plasmin were found to bind more tightly and transferrin was
collected in the eluate. Albumin and caeruloplasmin were
displaced from the column by elution with 2 M NaCl. The column
was re-equilibrated with 20 mM Tris/HCl (pH 8.0) and the process
repeated twice until transferrin bound to the column without
being displaced, indicating that the other proteins had been
removed. Once bound to the column, transferrin was eluted using
a salt gradient of 20 mM Tris/HCl and 0.2 M NaCl. Fractions
were pooled and samples resolved by SDS/PAGE (8% gels) to
confirm the purity of the purified transferrin. Selected fractions
were then dialysed against deionized water overnight at 4 ◦C and
subsequently freeze-dried.
Preparation of diferric transferrin
Although an excess of Fe–NTA was added to the solution to
completely saturate transferrin during the purification process, a
mixture of all four forms of transferrin are usually present in the
final product. In order to completely saturate the transferrin,
the freeze-dried product was dissolved in 0.1 M sodium
bicarbonate and 0.1 M Fe–NTA was added, with the volume re-
quired calculated using eqn (1). A Sephadex G-25 column
(30 cm × 3 cm radius) was equilibrated with 25 mM ammonium
bicarbonate and the transferrin solution was applied. This process
removed excess Fe–NTA. The transferrin sample was again
freeze-dried and stored at −20 ◦C.
Transfer of iron from hydroxypyridinones to DFO
A 1 mM stock solution of HPO was prepared in water and treated
with atomic absorption standard iron, to which 50 mM Mops
buffer (pH 7.4) was subsequently added. The final total concen-
trations of iron and HPO in the solution were 10 µM and 30 µM
respectively. The HPOs are bidentate chelators and therefore a
3-fold molar excess of HPO over iron is required to fully complex
the iron in solution. When additional citrate (300 µM) or HPO
(100 µM) were needed, the required quantity of either citric
acid or HPO was subsequently added to the preformed iron(III)
complex.
A solution of DFO was prepared in water and added to the
Fe/HPO solution, to give a final concentration of 10 µM DFO.
The transfer of iron was monitored by spectroscopy at room
temperature (20 ◦C). The Fe–DFO complex has an absorbance
maximum at 430 nm and the Fe–HPO complexes have maxima
in the region of 450 nm–460 nm, therefore the transfer of iron
from one chelator to the other can be monitored by UV–visible
spectroscopy. In most cases, the absorbance was monitored at a
wavelength of 455 nm. The rates of iron transfer were calculated
using the method of Rose [18].
Iron removal from transferrin: urea polyacrylamide gels
Diferric transferrin (32.5 µM) was prepared in 50 mM Mops
buffer (pH 7.4). A combination of bidentate chelators, followed
by DFO, were added and the sample was incubated for 2 h at
37 ◦C. The sample was then resolved on a urea polyacrylamide
gel. Urea gels (6 M) were prepared as described previously [19].
Transferrin samples were dissolved in sample buffer [0.01%
(w/v) bromophenol blue and 10% (w/v) glycerol in 0.089 M
Tris base, 0.089 M boric acid and 2 mM EDTA (pH 8.3)] prior to
loading on to the gel. The gel was run at 80 V overnight. The bands
were visualized by the addition of Coomassie Blue stain [0.25%
(w/v) Coomassie Blue, 9% (v/v) acetic acid and 45.5% (v/v)
methanol]. After de-staining [10% (v/v) acetic acid and 10%
(v/v) methanol], the relative percentages of each of the forms of
transferrin were calculated using densitometry scanning.
When iron removal from transferrin was investigated in the
presence of serum, the sample buffer was replaced with Rivanol
solution [0.375% (w/v) Rivanol and 10% (w/v) glycerol in
0.089 M Tris base, 0.089 M boric acid and 2 mM EDTA (pH 8.3)].
Rivanol is a dye which precipitates out γ -globulins, leaving
transferrin in the supernatant [19]. A 25 µl aliquot was removed
from the serum mixture, and 200 µl of Rivanol solution added.
This mixture was centrifuged at 2000 g for 3 min, and 20 µl of
the supernatant was loaded on to the gel. The gel was then run
at 80 V overnight. Normal serum samples were iron-loaded with
Fe–NTA. The amount of Fe–NTA added was calculated so that the
transferrin would not be completely saturated, thereby decreasing
the likelihood of the presence of NTBI (non-transferrin-bound
iron). The saturation of transferrin in these experiments was
approx. 80%, as determined by densitometry scanning of urea
gels.
The percentage iron saturation of transferrin was calculated by
determining the percentage of each of the four forms of transferrin
using densitometry scanning of urea gels and calculated using the
following equation:






where Tf is transferrin, C-Tf is C-monferric transferrin, N-Tf is
N-monoferric transferrin and sat. is saturation.
Iron removal from transferrin: FO (ferrioxamine) assay
Diferric transferrin (32.5 µM) in 20 mM Mops buffer (pH 7.0)
was incubated with a combination of bidentate chelators and
DFO at various concentrations at 37 ◦C. Aliquots were removed
at regular time intervals and ultrafiltered through 30 kDa filters
(Whatman) by centrifugation at 15000 g for 5 min to remove the
protein. The filtrate (50 µl) was then injected on to the HPLC
column for analysis.
A metal-free HPLC system (Waters Bio-system 625 with 911
Photodiode Array detector) with PEEK (polyether-ethyl ketone)
tubing was used in order to prevent iron contamination of the
samples. A Chrompak ODS (octadecylsilane) glass column was
used, and the flow rate was set at 0.4 ml/min. The temperature of
the injector was maintained at 4 ◦C during the analysis to minimize
any changes in the rate of reaction while the samples were in
the autosampler. The detection wavelength was set at 430 nm
to detect FO. The mobile phase consisted of 20 mM phosphate
buffer, pH 7.0, with 6% (v/v) acetonitrile (Rathburn Chemicals,
Walkerburn, Peeblesshire, U.K.), yielding a retention time of
6 min for FO. All samples were prepared in 20 mM Mops buffer
(pH 7.0). The concentration of FO in the samples was determined
by use of a standard concentration curve of FO.
Speciation plots
Speciation plots of the iron complexes of deferiprone and
CP511 were generated using the computer program Hyperquad
Simulation and Speciation (HySS) [20]. The parameters
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 1 Rate profile of iron transfer from CP358 to DFO
Iron transfer from CP358 to DFO measured as a decrease in absorbance at 455 nm in
50 mM Mops buffer (pH 7.4) at room temperature. [Fe] = 10 µM, [CP358] = 30 µM and
[DFO] = 10 µM.
incorporated for speciation plot generation were logK(FeOH) =
2.563, logK[Fe(OH)2] = 6.205, logK[Fe(OH)4] = 21.883, logK-
[Fe2(OH)2] = 2.843 and logK[Fe3(OH)4] = 6.054 [21]. For
deferiprone: logK1 = 15.1, logK2 = 11.51, logK3 = 9.27 [22],
pKa1 = 3.68 and pKa2 = 9.77 [23]. For CP511: logK1 = 14.5,
logK2 = 10.49, logK3 = 7.47, pKa1 = 2.32 and pKa2 = 6.66 [16].
RESULTS
Iron transfer between hydroxypyridinones and DFO
An absorption trace recording iron transfer from CP358 to DFO
is shown in Figure 1. It can be seen that the transfer of iron from
the bidentate chelator to DFO follows a biphasic pattern, with
a relatively fast initial transfer followed by a slower phase. A
similar pattern was observed for the rate of iron transfer from all
the HPO chelators tested in this study. This observation can best be
explained by a two-step iron transfer mechanism, where the initial
fast phase corresponded to the formation of a ternary Fe/HPO/
DFO mixed-ligand complex, followed by the slower formation of
the Fe–DFO complex (Scheme 1). The initial rates of transfer
of iron from various Fe–HPO complexes (10 µM Fe and 30 µM
HPO) to 10 µM DFO are presented in Figure 2. It can be seen
that there is an appreciable variation in the rate of iron transfer.
CP95 was the most effective chelater at transferring iron under
the experimental conditions used. The rate of iron transfer from
deferiprone and CP40 to DFO was approx. 1.5-fold slower than
that observed from CP95 to DFO. CP363 and CP375, which
are higher-affinity chelators, had rates of iron transfer similar
to that of deferiprone. The slowest rates of iron transfer to
DFO were observed with CP357, CP358, CP506 and CP511.
These iron transfer experiments were repeated in the presence of
300 µM citrate, a physiological iron chelator present in plasma,
and the rate of transfer of iron from the majority of the HPO
chelators to DFO was reduced by approx. 1.5-fold. However,
the converse was noted in the case of iron transfer from CP357
and CP358 to DFO, with the addition of citrate resulting in a
2-fold increase in the rate of iron transfer to DFO (results not
shown).
Under in vivo conditions, a major proportion of the administered
dose of a chelator would be present in the unchelated form. It
was therefore decided to examine the rate of iron transfer from
HPO to DFO in the presence of 100 µM excess HPO chelator
(Figure 3). The results are presented as the ratio of the rate of iron
Figure 2 Rate of iron transfer from Fe-HPO to DFO
Initial rates of iron transfer from Fe–HPO (10 µM Fe and 30 µM HPO) complexes to 10 µM
DFO in 50 mM Mops buffer (pH 7.4) at room temperature. Results are means +− S.D. (n = 3).
The black bars represent higher-affinity chelators, the grey bars represent lower-affinity chelators
and the white bars represent chelators possessing large ring substituents.
Figure 3 Ratio of the rate of iron transfer from Fe–HPO in the presence of
excess HPO to DFO compared with the rate of iron transfer from a 1:3 molar
concentration of Fe:HPO to DFO
Rate of iron transfer from the Fe–HPO (10 µM:30 µM) complex in the presence of 100 µM
excess HPO to 10 µM DFO in 50 mM Mops buffer (pH 7.4) at room temperature. Results are
the ratio of the rate of iron transfer in the presence of excess HPO compared with the rate of
transfer in the presence of a 1:3 molar ratio of Fe/HPO. The black bars represent higher-affinity
chelators, the grey bars represent lower-affinity chelators and the white bars represent chelators
possessing large ring substituents.
transfer to DFO in the presence of excess HPO chelator against
the rate of iron transfer to DFO in the presence of a 1:3 ratio
of iron to HPO (with no excess chelator). All of the rates were
markedly reduced in the presence of excess chelator. Significantly,
the rates of iron transfer from the lower-affinity chelators CP95
and deferiprone were the least affected by the presence of excess
HPO. The presence of excess HPO had the greatest effect on the
transfer of iron from the chelators CP357, CP358, CP506 and
CP511.
Iron transfer from the Fe–DFO complex, FO to deferiprone was
investigated at both pH 5.5 and pH 7.4 in order to verify whether
FO could act as an efficient sink and prevent the redistribution of
iron under both extracellular conditions and lysosomal conditions.
At deferiprone concentrations less than 300 µM, there was no
detectable transfer of iron to deferiprone at either pH 5.5 or 7.4.
As the concentration of deferiprone was increased above 300 µM,
transfer of iron occurred, with the transfer at pH 5.5 greater
than transfer at pH 7.4 (Figure 4). However, these latter
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 4 Rate of iron transfer from DFO to deferiprone
Iron transfer from the FO (10 µM) complex to various concentrations of deferiprone at pH 5.5
[20 mM acetate buffer (20 mM sodium acetate/acetic acid)] () and pH 7.4 (20 mM Mops buffer)
(). Incubations were performed at room temperature. Results are means +− S.D. (n = 3).
deferiprone concentrations would not be observed under clinical
conditions.
Iron exchange between transferrin and chelating agents
Having established that the transfer of iron from the bidentate che-
lators to DFO occurred under clinically relevant chelator concen-
trations, it was of interest to examine whether this transfer of iron
would result in enhanced scavenging of iron from transferrin.
This was examined by urea PAGE, and a respresentative gel is
shown in Figure 5. Lane 1 shows a single band corresponding to
diferric transferrin. Lanes 2 and 3 show the presence of 4 bands,
namely apotransferrin, C-monoferric transferrin, N-monoferric
transferrin and diferric transferrin, following a 2 h incubation
of diferric transferrin with 200 µM and 600 µM deferiprone
respectively. The iron saturation of transferrin decreased with
increasing chelator concentration. A combination of bidentate
chelators and DFO were incubated with transferrin and iron
removal was monitored using urea PAGE. Three chelators were
chosen for this study: deferiprone, CP358 and CP502; both CP358
and CP502 are analogues of deferiprone (Table 1). CP358 is a
larger chelator, which has a bulky side-chain and is therefore
not expected to be able to efficiently chelate iron from the iron-
binding sites of transferrin. CP502 is a small, higher-affinity iron
chelator, which should be more effective at iron removal from
transferrin in comparison with deferiprone. No iron removal was
observed in the presence of 100 µM DFO alone. Transferrin
was incubated with a range of deferiprone concentrations in the
presence or absence of 100 µM DFO (results not shown). At
deferiprone concentrations greater than 1 mM, a large percentage
of the iron was removed from transferrin (approx. 60%). At this
concentration of deferiprone, further addition of 100 µM DFO
resulted in enhanced iron removal, with approx. 75% of the iron
removed from transferrin. As the concentration of deferiprone
was increased up to 5 mM, almost all the iron was removed
from transferrin, but further addition of DFO had virtually no
effect. In humans, following administration of a 25 mg/kg dose
of deferiprone, the maximal concentration of the drug in the
plasma is approx. 100 µM [24]. The steady-state concentration
of DFO during a 40 mg/kg intravenous infusion is 10 µM [25].
Iron removal from transferrin was therefore investigated in the
presence of a range of HPO chelators (100 µM) in the presence
or absence of 10 µM DFO (Table 2). In all cases, an increase
in iron removal from transferrin was observed when DFO
was combined with HPO compared with HPO alone; however,
statistical significance was not reached. When the concentration of
HPO was further reduced to 50 µM and the DFO concentration
Figure 5 Urea gel showing the four forms of transferrin
A urea gel showing the effect of high deferiprone concentrations on the saturation of
transferrin. Lane 1 depicts diferric transferrin. Lane 2 depicts apotransferrin, C-monoferric trans-
ferrin, N-monoferric transferrin and diferric transferrin, obtained following the incubation of
diferric transferrin with 200 µM deferiprone for 2 h at room temperature. Lane 3 depicts
apotransferrin, C-monoferric transferrin, N-monoferric transferrin and diferric transferrin,
obtained following the incubation of diferric transferrin with 600 µM deferiprone for 2 h at room
temperature.
Table 2 Percentage iron removal from transferrin in the presence of 50 µM
HPO +− 10 µM DFO and 100 µM HPO +− 10 µM DFO
Diferric transferrin (32.5 µM) was incubated with 50 or 100 µM HPO in the presence or absence
of 10 µM DFO for 2 h at 37◦C in 50 mM Mops buffer (pH 7.4). Results are means +− S.D. (n = 3).
No statistical significance was observed between the values for iron removal from HPO alone
compared with HPO and DFO using the Student’s t test. The percentage of iron removed was
calculated using densitometry scanning.
Iron removal from transferrin (%)
50 µM HPO + 100 µM HPO +
HPO 50 µM HPO 10 µM DFO 100 µM HPO 10 µM DFO
Deferiprone 4.7 +− 2.6 6.0 +− 2.1 5.8 +− 1.9 13.9 +− 5.2
CP502 5.5 +− 1.5 5.7 +− 1.1 13.5 +− 5.2 17.5 +− 8.0
CP358 2.8 +− 1.7 4.8 +− 1.4 8.3 +− 6.2 14.0 +− 2.2
maintained at 10 µM (Table 2), weakly enhanced scavenging of
iron was seen when DFO was combined with deferiprone and
CP358, but not with CP502.
The rate of iron removal from 80% saturated transferrin in
serum was also investigated. Combinations of HPO and DFO
were incubated with serum samples (Figure 6), and the amount
of iron removed by 100 µM deferiprone alone in the presence of
serum was found to be comparable with that removed from
purified transferrin (Table 2). Addition of 10 µM DFO did not
result in an increase in the amount of iron removed from transferrin
when compared with 100 µM HPO alone. However, in the
presence of equimolar concentrations of deferiprone and DFO,
a significant increase in iron removal from serum transferrin was
observed when compared with deferiprone alone. The addition of
200 µM deferiprone did not result in any further increase in iron
removal compared with 100 µM deferiprone. The combination
of CP502/DFO did not result in enhanced scavenging activity,
even at high concentrations of chelator; however, the combination
of 100 µM CP358 and 100 µM DFO did result in marginal
enhancement of iron removal (Figure 6).
Iron removal from iron-saturated transferrin was also monitored
using the FO assay (Figure 7). The addition of 10 µM DFO
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 6 Iron removal from serum transferrin
Serum samples were incubated with equimolar concentrations of HPO and DFO (either 100 µM
each or 200 µM each) at 37◦C as follows: (A) deferiprone and DFO, (B) CP358 and DFO, and
(C) CP502 and DFO. Dark grey bars denote HPO alone, light grey bars denote HPO in the presence
of an equimolar concentration of DFO. Iron removal from transferrin was calculated using
densitometry scanning. Results are means +− S.D. (n = 6). Asterisk (*) denotes a significant
difference between HPO alone and the combination of HPO and DFO, determined using the
Student’s t test at the 5 % significance level.
alone resulted in marginal (non-significant) iron removal from
transferrin. The addition of 30 µM deferiprone resulted in a
large increase in the rate of iron removal. Addition of 100 µM
deferiprone to 10 µM DFO resulted in slightly greater FO form-
ation compared with that observed in the presence of 30 µM
deferiprone and 10 µM DFO (results not shown). It is clear that
the FO assay is more sensitive than the urea gel method for deter-
mining iron removal from transferrin at lower chelator
concentrations.
DISCUSSION
Although current chelation therapy, namely the use of either DFO
or deferiprone, is effective at increasing the life expectancy of
patients with transfusion-dependent anaemias, there are some
disadvantages associated with their use. It has been hypothesized
Figure 7 Iron removal from transferrin measured by FO formation following
incubation with deferiprone and DFO
Transferrin (32.5 µM) was incubated with 30 µM deferiprone and 10 µM DFO () and 10 µM
DFO alone (). Samples were prepared in 20 mM Mops buffer (pH 7.0) and incubated at 37◦C.
Results are means +− S.D. (n = 3). Asterisk (*) denotes a significant difference between DFO
alone and the combination of deferiprone and DFO, determined using the Student’s t test at the
5 % significance level.
that the combined administration of these two chelators may
increase the total amount of iron removed from the body, without
an increase in chelator dose [7]. Studies have been carried out
which indicate that combined chelation therapy may not only
prove to be effective at decreasing body iron burden, but may
also decrease the cost and increase compliance with these pharm-
aceuticals [26].
It has been suggested that enhanced scavenging activity aris-
ing from combined chelation therapy is based on the transfer
of iron from the smaller bidentate chelator to the hexadentate
chelator (Scheme 1) and is therefore dependent on the rate
of iron transfer between the two chelators [7]. In this present
study, the rate of iron transfer between a range of bidentate
HPO chelators and DFO was determined using UV–visible spec-
troscopy (Figure 1). The lower-affinity chelators deferiprone and
CP95 (pFe3+ values of 19.4 and 19.9 respectively) were the
most effective at iron transfer to DFO. The rates of iron transfer
from CP357 and CP358 to DFO were approx. 2-fold lower than
the rate of iron transfer from CP95. Both of these compounds
possess long side-chains at the 2′ position on the pyridinone
ring. The presence of this side-chain could possibly interfere
with the formation of the postulated DFO ternary complex
(Scheme 1). The high-affinity chelators are the slowest iron
donors to DFO, and this is probably the result of a decrease
in the rate of dissociation of the Fe(HPO)3 complex to the
intermediary Fe(HPO)2 complex [27], which is suggested to be
necessary for DFO chelation (Scheme 1). From these results, it
appears that there is a limited relationship between the pFe3+
value and the rate of transfer of iron to DFO, with an increase in
pFe3+ resulting in a decrease in the rate of transfer. However, other
structural factors must also be involved in controlling the rate of
transfer of iron from the bidentate chelator to DFO, since both
CP95 and CP40, which have similar pFe3+ values to deferiprone,
have much slower rates of transfer. In the presence of citrate, the
rate of transfer of iron from HPO to DFO was decreased by approx.
1.5-fold in most cases (results not shown). The high concentration
of citrate could possibly encourage transfer of iron to citrate. Once
formed, dimeric and oligomeric iron–citrate species [28], which
are not readily accessible to DFO, would be predicted to retard
the rate of iron transfer to DFO.
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Figure 8 Speciation plots of iron–deferiprone and iron–CP511 complexes
Speciation plots showing all complexes of iron and HPO and the predominant iron
hydroxide species. (A) Iron–deferiprone speciation plot, (B) iron–CP511 speciation plot.
[Fe]3+ total = 1 × 10−5 M, [HPO] = 3 × 10−5 M. Broken lines show amounts of Fe(HPO)2
and Fe(HPO)3 present at pH 7.4. The plots were generated using HySS [20].
The marked retardation in the rate of exchange in the presence
of excess chelator (Figure 3) is almost certainly associated with a
shift in equilibrium of the dissociation process (Scheme 1). In the
presence of excess chelator, the equilibrium will adjust, favouring
the formation of the Fe(HPO)3 complex, which will not donate
iron to DFO, thereby reducing the rate of transfer. The lower-
affinity chelators, such as deferiprone, CP40 and CP95, are not
as greatly affected as the higher-affinity chelators and the bulky
chelators. Thus even in the presence of excess chelator, the lower-
affinity chelators are more likely to dissociate from iron than
the higher-affinity chelators, and therefore the rate of iron transfer
from these chelators is likely to be greater. The relative proportions
of the partially co-ordinated Fe(HPO)2 complex under any given
condition can be calculated from speciation plots. Comparing the
speciation plots obtained for deferiprone and CP511 at pH 7.4
provides an insight into the reasons for the variation in rates of
transfer of iron from these two chelators to DFO (Figure 8). The
presence of a higher proportion of the Fe(deferiprone)2 complex
compared with the Fe(CP511)2 complex demonstrates that the
higher pFe3+ of CP511 results in a decrease in the dissociation of
the Fe(HPO)3 complex compared with deferiprone, and thereby
decreases the rate of iron transfer to DFO. Even in the presence of a
3-fold molar excess of HPO compared with iron, a proportion of
partially co-ordinated Fe(HPO)2 will exist in solution, the exact
concentration of which depends on the pFe3+ of the chelator.
To determine the efficacy of DFO as a sink molecule, the rate
of transfer of iron from the Fe–DFO complex to deferiprone was
investigated. The slow rates of transfer demonstrate that once iron
is chelated by DFO, it is highly improbable that the iron could
be mobilized under clinically achievable HPO concentrations.
Thus although greater iron removal was observed at pH 5.5, the
concentration of deferiprone required to mobilize iron was much
higher than would be present under clinical conditions. Clearly
DFO acts an effective sink molecule and so is a good candidate
for combined chelation therapy with HPOs, such as deferiprone.
After the demonstration that transfer of iron from bidentate
chelators to DFO occurs under clinically relevant concentrations
of chelator, the interaction of chelators with transferrin was
investigated. Transferrin-bound iron is not readily accessible to
DFO, and so it was of interest to determine whether this iron
could be chelated in the presence of both a bidentate HPO and
DFO. At high deferiprone concentrations, the combination of
deferiprone and DFO resulted in marginally greater iron removal
from transferrin compared with deferiprone alone.
Having demonstrated that enhanced scavenging in the presence
of a combination of chelators is observed for iron removal from
transferrin at high deferiprone concentrations, chelator concen-
trations were reduced to simulate conditions achievable in vivo
(Table 2). In the absence of DFO, CP502 was found to be the most
effective at removing iron from transferrin. CP502 has the
highest affinity for iron out of the chelators tested and is also
relatively small, thereby enabling access to the iron-binding sites
on transferrin. CP358 would be restricted in its access to the
iron-binding sites on transferrin, because of the larger size of
the molecule. In the presence of DFO, there is also a variation
in the enhancement in iron removal observed with each HPO
chelator, with a greater increase observed with the combination
of deferiprone and DFO (approx. 2.4-fold increase in iron removal
compared with deferiprone alone) and lower increases observed
with the combination of CP502/DFO and of CP358/DFO (approx.
1.3-fold and 1.7-fold increases in iron removal respectively when
compared with either HPO chelator alone). The reason for this
discrepancy in scavenging activity between the HPO chelators is
probably the result of their relative abilities to transfer iron to
DFO. The rate of iron transfer from CP502 and CP358 to DFO is
slower when compared with deferiprone (Figure 2).
Although purified transferrin has been shown to be an effective
model for iron removal studies, experiments were also carried
out using iron-loaded serum samples (Figure 6). The total iron
removed from transferrin in serum by 100 µM HPO alone was
comparable with that achieved from purified transferrin. The
addition of equimolar concentrations of deferiprone and DFO
resulted in appreciable enhancement of iron removal. In contrast,
the combination of CP358/DFO and of CP502/DFO failed to
demonstrate such an effect. The most probable reason for this
marked difference in behaviour is that both CP358 and CP502 do
not donate iron(III) to DFO as readily as deferiprone (Figures 2
and 3).
It was not possible to use urea gel analysis to monitor iron
removal from transferrin in the presence of low concentrations of
bidentate chelator (for example, 30 µM). Therefore an alternative
procedure based on the quantification of FO was adopted to
monitor iron removal from transferrin at lower concentrations
of bidentate chelator. This method provided a time course for the
removal of iron. Any increase in FO formation in the presence
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of deferiprone must have occurred as a result of the shuttling of
iron from transferrin to DFO by the bidentate chelator, as
DFO is unable to directly remove iron from transferrin under
these conditions. Iron removal using a combination of 30 µM
deferiprone and 10 µM DFO resulted in faster iron removal
compared with DFO alone (Figure 7). The complete conversion
of DFO to FO takes approx. 5 h. A similar effect was observed
with 100 µM deferiprone. This observation confirms the findings
reported previously which relate to the iron removal from
transferrin by deferiprone [9].
The experiments described in this present study demonstrate
that the combination of the bidentate chelator deferiprone and the
hexadentate chelator DFO results in enhanced scavenging activity
of iron from transferrin at clinically achievable levels of both
chelators. In the presence of DFO, this mobilized iron is donated
to the hexadentate ligand (Figures 2 and 3). Thus it is possible to
predict that simultaneous administration of the two ligands will
lead to more efficient removal of iron from iron-overloaded
patients. Furthermore, it is suggested that the combination of
a chelator, such as deferiprone, with a sink molecule, such as
DFO, could further improve the efficacy of chelation of tissue
iron by ligand exchange of iron. It should be noted, however, that
enhanced scavenging activity of iron may also lead to increased
toxicity owing to enhanced iron removal from essential iron-
containing enzymes. HPO chelators have been shown to inhibit
lipoxygenase activity in vitro [29], an effect which may be
accentuated in the presence of a sink molecule, such as DFO.
Inhibition of ribonucleotide reductase [30] and tyrosine and
tryptophan hydroxylases [31] have also been shown to occur in the
presence of HPO chelators. Limited information exists regarding
the toxic effects of combined chelation therapy.
Combined chelation therapy with deferiprone and DFO has
been demonstrated to enhance iron scavenging activity in vivo
in a number of clinical cases and has been shown to be
especially beneficial in decreasing cardiac iron burden [32]. This
phenomenon has been attributed to the shuttling of iron from
the bidentate chelator to the hexadentate chelator [7,33]. It has
been established previously that deferiprone removes iron from
transferrin. However, the present study is the first to conclusively
demonstrate that in the presence of both deferiprone and DFO
in vitro, the chelated iron is shuttled on to DFO to form the
FO complex, which is not formed in the absence of deferiprone.
This phenomenon demonstrates the possibility of shuttling iron
from a bidentate chelator to a hexadentate chelator and the
subsequent removal of iron from a source unavailable to DFO
alone.
In summary, the results presented here demonstrate that in the
presence of a bidentate and a hexadentate chelator, enhanced iron
scavenging activity occurs at clinically relevant chelator concen-
trations and, among the HPO chelators, deferiprone would appear
to be particularly well suited for such applications.
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